Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "MMP3" patented technology

Stromelysin-1 also known as matrix metalloproteinase-3 (MMP-3) is an enzyme that in humans is encoded by the MMP3 gene. The MMP3 gene is part of a cluster of MMP genes which localize to chromosome 11q22.3. MMP-3 has an estimated molecular weight of 54 kDa.

Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

InactiveUS20120172244A1Technically accurateImproved accurate quantifierSugar derivativesHydrolasesOncologyTreatment strategy
Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.
Owner:UNIV OF NOTRE DAME DU LAC

Method to measure inflammation in the conjunctiva of patients with tear dysfunction

InactiveUS20140314798A1Unsuitable for treatmentBiocideTetracycline active ingredientsConjunctivaOcular surface
The present invention concerns methods and compositions for treatment and determination of the presence or likelihood of an individual to have an ocular surface inflammation. In specific embodiments, a sample from the individual is assayed for the expression level of three or more genes, including IL-6, MMP3, MMP9, IFNy, SPRR-IA, HLA-DRA, MUC5AC, K7, and IL17A. Treatment is provided to an individual with ocular surface inflammation based upon the gene analysis.
Owner:BAYLOR COLLEGE OF MEDICINE

Separated nucleic acid sequence of total number of piglets related gene MMP3

InactiveCN101481740AOvercoming the shortcomings of conventional selection for reproductive traitsMicrobiological testing/measurementDNA/RNA fragmentationMarker-assisted selectionIntein
The invention relates to a separated nucleic acid sequence of a total number born trait related gene MMP3 of a pig in the technical field of genetic engineering. The separated nucleic acid sequence is provided with a sequence shown by an SEQ ID No:1, the length of which is 1346bp; the nucleic acid sequence shows a pair of allele-specific nucleic acid primers the lengths of which are 20bp; the pair of nucleic acid primers is specifically hybridized; and the sequence shown by the SEQ ID No:1 containing an eighth exon, a ninth exon and an eighth intron of the MMP3 gene of the pig is amplified. The implementation and the application of the separated nucleic acid sequence can be used for detecting and judging the quality of total number born traits of the pig; the molecular marker is applied to conduct a marker assisted selection during breeding of the pig, thereby correcting the defect during conventional selection of reproductive traits of the pig; and the separated nucleic acid sequence has important practical significance.
Owner:SHANGHAI JIAO TONG UNIV

Stratification of Left-Side and Right-Side Colon Cancer

Compositions / methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment / stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and / or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and / or RCC patient is also presented.
Owner:UNIV OF NOTRE DAME DU LAC

Functionalized self-assembly miRNA/polypeptide composite hydrogel suitable for cartilage regeneration and preparation method thereof

The invention discloses a functional self-assembly miRNA/polypeptide composite hydrogel suitable for cartilage regeneration and a preparation method of the functional self-assembly miRNA/polypeptide composite hydrogel. The preparation method comprises the following steps: (1) preparing a functional polypeptide aqueous solution; (2) obtaining original miRNA from sample sequencing sources of aged animals and human bodies with arthritis, and further selecting phenotypes of arthritis and aging, including Sox9, Acan, Col2a1, Mmp3, Mmp13, P16INK4a, P21, Adamts4 and Adamts5, by virtue of a fluorescent quantitative PCR (Polymerase Chain Reaction) technology and western blotting, so as to determine the miRNA with the functions of resisting aging and promoting cartilage repair, and further selecting the phenotypes of the arthritis and aging, including Sox9, Acan, Col2a1, Mmp3, Mmp13, P16INK4a, P21, Adamts4 and Adamts5; (3) dissolving the miRNA with the anti-aging and cartilage repair promoting functions determined in the step (2) by using the functional polypeptide aqueous solution to obtain a composite solution; and (4) placing the composite solution in a crosslinking condition for in-situ crosslinking to obtain the functionalized self-assembled miRNA/polypeptide composite hydrogel suitable for cartilage regeneration.
Owner:方向前 +1

Composition for combined treatment of solid tumors

The invention discloses a composition for combined treatment of solid tumors, and the effective component at least includes an mmp3 antagonistic substance and an oncolytic virus. The composition usesthe mmp3 antagonistic substance and the oncolytic virus to perform combined treatment on the solid tumors, and can effectively inhibit tumor growth and improve survival rate.
Owner:SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products